Abstract-While the increase in cardiac work, force and rate are known to be a func tion of beta-adrenergic receptor stimulation, the mechanism of metabolic actions is uncertain. This study was undertaken to clarify the &ldquo;calorigenic&rdquo; action of epine phrine and its relation to hemodynamic changes. In a group of canine heart-lung preparations, the intra-atrial infusion of 0.01, 0.03 and 0.1 &mu;g/kg of epinephrine did not change the cardiac work, force and rate, of the myocardial oxygen consumption, as compared to the control. However, intra-atrial infusion of 0.5 &mu;g/kg of epine phrine caused an increase in cardiac work, cardiac isometric contraction, coronary flow and a marked elevation in the myocardial oxygen consumption above and beyond the rate of its effect on the cardiac hemodynamic parameters.
phrine caused an increase in cardiac work, cardiac isometric contraction, coronary flow and a marked elevation in the myocardial oxygen consumption above and beyond the rate of its effect on the cardiac hemodynamic parameters.
Addition of 0.5 mg/kg of Sotalol did not cause depression of these parameters of left ventricular functions, including the coronary flow. However, 0.5 mg/kg of Sotalol effectively blocked the &ldquo; calorigenic&rdquo; action of 0.5 &mu;g/kg of epinephrine.
Apparently, more oxygen is being extracted by the myocardium after 0.5 &mu;g/kg of epinephrine.
Sotalol blocks this calorigenic action of epinephrine.
Since the metabolic effects of epinephrine have not been shown to be beta-adrenergic receptor-mediated changes, it is concluded that Sotalol has the unique property of blocking the metabolic action of epinephrine.
According to investigators, the increased metabolic activity which is produced in the myocardium by epinephrine was thought to be secondary to the increased cardiac con tractile activity (1, 2, 3, 4, 5) . Epinephrine apparently increases oxygen consumption rate and augments the reduction of ATP concentration only in working heart muscle and not in resting muscular preparations (1, 2, 3) . Recent evidence, however, suggests that epinephrine may possess certain calorigenic effects (6), especially at relatively low doses, which are not accompanied by a concomitant rise in the cardiac contraction or work.
Catecholamines may cause "oxygen wasting" in the heart and other organs in vivo (7, 8) .
The effects of epinephrine on cardiac hemodynamic actions, including the work, force developed and the rate, are known to be a function of beta-adrenergic receptor stimula tion (5) . The mechanism of metabolic actions of epinephrine is however uncertain (9).
The present study was undertaken to clarify the metabolic actions of epinephrine and the relationship to hemodynamic changes. This was carried out by applying a beta adrenergic receptor blocking agent, Sotalol, dl-4-(20 isopropylamino l-hydroxyethyl) methanesulfonanilide. Sotalol, also known as MJ-1999, has been reported to exert a selective blockade on beta-adrenergic receptors without undue depression of the heart (10, 11).
MATERIALS AND METHODS Twenty mongrel dogs of both sexes weighing 17-22 kg were anesthetized with 30 mg/kg of IN. sodium pentobarbital. A heart lung preparation was made in the classical manner with the following modifications. A cannula was sutured into the orifice of the coronary sinus and a Shipley-Wilson rotometer was used to measure coronary sinus flow. Aortic flow was measured by a second rotometer connected to a Starling resistance unit. Cardiac output was obtained by adding coronary sinus flow to aortic flow. The aortic pressure was kept at a constant level of 80 mmHg throughout the study by adjusting the Starling resistance unit. A catheter was inserted into the appendage of the left atrium and at tached to a Statham transducer for pressure measurements. Blood samples collected from the aorta and coronary sinus were analyzed for oxygen content by the Van Slyke manometric method. The left ventricular function curve was constructed by changing the level of the venous reservoir from 5 to 10 to 15 cm heights. The left atrial pressure, heart rate, cardiac output, cardiac work, coronary sinus flow (ml/min/100 g heart) and myocardial oxygen consumption (ml Oz/min/g heart) were measured. The first derivative of rise in left ventricular pressure (dP/dT) was measured throughout the study using left ventricular and aortic blood pressure tracings recorded at a paper speed of 100 mm/sec.
A ventricular function curve was constructed in the first group of dogs by elevating the venous reservoir. After obtaining the control values of left ventricular function, the process was repeated after right atrial infusion of epinephrine (0.01 p4g/kg) for one, three and ten min durations.
A ventricular function curve was constructed in the second group of dogs and the control variables mentioned previously were recorded. Each variable was evaluated after right atrial infusion of epinephrine (0.1 /eg/kg/min) for five min. With the return of con trol levels, Sotalol (0.5 mg/kg) was added to the venous reservoir, ventricular function curve was again reconstructed and values recorded for each cardiac variable. After a control state had been re-established, right atrial infusion of epinephrine (0.1 14g/kg) was given for five min. Sotalol (0.5 mg/kg) was added to the venous reservoir and cardiac values were re-evaluated.
RESULTS
Elevation of the venous reservoir caused an increase in left atrial pressure. The left ventricular function curve ( Fig.) showed a linear correlation between cardiac output (Y) and left atrial pressure (X), which follows the regression formula of Y=0.0944X-i-0.1235; r=0.927; t=13.433 and p<0.001.
The curve remained at control levels when 0.01, 0.03 and 0.1 , g/kg of epinephrine, 0.5 mg/kg Sotalol plus 0.5 /Ig/kg of epinephrine were given. However, 0.5 pg/kg of epine phrine caused a shift to the left which had a linear regression formula of Y=0.1535X 0.1070; r=0.9981; t=22.177 and p<0.001 (Fig. 1) . The coronary sinus flow was increased with 0.5 fag/kg of epinephrine but was not altered from control values with Sotalol (0.5 mg/kg) (Figs. 2 and 3) . The sinus flow, after Sotalol (0.5 mg/kg) and epinephrine (0.5 /Ig/kg) had been administered simultaneously was similar to the flow recorded after epinephrine (0.5 fag/kg) alone.
Elevation of the venous reservoir also caused an increase in myocardial oxygen con sumption (qO2). Fig. 4 shows a linear correlation between qO2 (Y) and cardiac work (X) which follows the regression formula of Y=0.0012X ' 0.0617; r=0.7134; t=4.602 and p<0.005.
The curve remained at control levels when 0.01, 0.03 and 0.1 ,ug/kg of epinephrine, 0.5 mg/kg Sotal and 0.5 mg/kg Sotalol plus 0.5 1 g/kg of epinephrine were given. How ever, 0.5 jig/kg of epinephrine caused a shift to the left (Fig. 4) . Epinephrine has been reported to possess an "oxygen wasting" effect or "calorigenic" effect in the heart and other organs in vivo (7, 8) and our data concurs with these findings.
The increased oxygen utilized by the heart exceeds the increase in coronary flow, there fore, the heart must be extracting more oxygen from coronary blood.
Sotalol (0.5 mg/kg) blocked all of the cardiac effects of epinephrine (0.5 1 g/kg) except the increase in coronary blood flow. Other beta-receptorr blockers such as propranolol will block the effects of epinephrine, however, these, unlike Sotalol, cause cardiac depres sion (11) . Since the metabolic effects of epinephrine have not been shown to be beta receptor mediated changes (9) it is concluded that Sotalol may possess this unique pro perty of blocking the calorigenic action of epinephrine. It could be argued that the blockade of chronotropic changes induced by epinephrine (0.5 pg/kg) was the mechanism by which the increased oxygen consumption was blocked by Sotalol. It was found however, that trachycardia was not essential for increased oxygen consumption after epinephrine in heart lung preparations (12) . Data compiled in Fig.   7 concurs with these findings. Other investigators have suggested that factors other than contractile, rate or tension are responsible for increased oxygen consumption following epinephrine (13, 14) . Whatever the mechanism of oxygen consumption, it was blocked by Sotalol. It is tempting to conclude that this blockade of epinephrine's oxygen con sumption is responsible for its clinical anti-anginal properties.
